by Raynovich Rod | Oct 31, 2022 | Biopharmaceuticals
Update 2..-11/3…Powell curbs enthusiasm for stocks with harsh rhetoric. Get whipsawed? We get it, rates are going up Recent trades: bought HOLX, sold MRNA, bought more IHI. Biotech movers: BMY up 1.39%, LLY up 1.96%, ROIV up 6.655, VCYT up 24.25%. Veracyte grows...
by Raynovich Rod | Oct 24, 2022 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-1 10/28… Broad rally after Megacaps sell-off -AMZN, META and MSFT. it almost look like the BIG tech money got spread around to energy, financials, and healthcare. In the meantime the DOW is up 5.69% for the week and 10.73% for the month led by AAPL...
by Raynovich Rod | May 1, 2018 | Biopharmaceuticals
5/3 Testing February bottom and 200 MA of ~$100 on IBB and ~$85 on XBI. Red screen day. 2PM EDT Dow near flat line. Need to look for major gap up. Another potential negative on the horizon: “Bold Action on Drug Pricing” by Sect’y HHS. 5/2 Biotech...
by Raynovich Rod | Mar 6, 2018 | Biopharmaceuticals
Update-1 March 10… Broad Rally Continues Through The Week QQQ Up 4.3% IBB up 4.3% XBI up 4.8% Gene Editing Stocks Surge Biotech stocks soared along with the market as fear about interest rates, tariffs and global politics subsided helped considerably by economic...
by Rod Raynovich | Apr 21, 2010 | BIOgraph
Healthcare Reform Impact on Gilead HIV Product Sales Surprises Analysts Gilead Sciences (GILD) lowered its 2010 sales forecast to a range of $7.4-$7.5B from $7.6-$7.8B citing recently enacted healthcare legislation. Net income for the quarter ended March 31 jumped...